3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 1/2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Breast Neoplasms
92
Polycystic Ovary Syndrome
11
Neoplasm Metastasis
7
Infertility
5
Carcinoma, Ductal, Breast
5
Carcinoma, Lobular
4
Osteoporosis
3
Neoplasms, Hormone-Dependent
3
Neoplasms
3
Breast Neoplasms, Male
3
Advanced Breast Cancer
3
Fallopian Tube Neoplasms
2
Carcinoma, Ovarian Epithelial
2
Breast Carcinoma In Situ
2
Bone Diseases, Metabolic
2
Unilateral Breast Neoplasms
1
Recurrence
1
Peritoneal Neoplasms
1
Ovarian Neoplasms
1
Osteitis Deformans
1
Obesity
1
Neoplasms by Site
1
Multiple Endocrine Neoplasia Type 1
1
Low Grade Serous Ovarian Cancer
1
Infertility, Female
1
Hormone Receptor-Positive and HER2-Negative Advanced Breast Cancer
1
Hereditary Sensory and Autonomic Neuropathies
1
Hereditary Breast and Ovarian Cancer Syndrome
1
HR+/HER2- Breast Cancer
1
HER2+ Breast Cancer
1
Interventions
pembrolizumab
4
Gemcitabine
4
padeliporfin
3
napabucasin
3
Pemetrexed
3
Paclitaxel
3
Drug Therapy
3
Cisplatin
3
Carboplatin
3
130-nm albumin-bound paclitaxel
3
ribociclib
2
palbociclib
2
Mitomycin
2
Gonadotropin-Releasing Hormone
2
Fluorouracil
2
Bevacizumab
2
Anastrozole
2
Albumin-Bound Paclitaxel
2
AZD9833
2
valrubicin
1
selinexor
1
pralsetinib
1
patritumab
1
palladium-bacteriopheophorbide
1
linifanib
1
ipatasertib
1
enfortumab vedotin
1
camrelizumab
1
atezolizumab
1
abemaciclib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Neoplasms by Site
×
Letrozole
×
Clear all
NCT04964934
2026-04-21
SERENA-6
AstraZeneca
Phase 3
Active not recruiting
315 enrolled